{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T08:04:32Z","timestamp":1777363472009,"version":"3.51.4"},"reference-count":15,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>The separation of benign from malignant mesothelial proliferations is a difficult morphologic problem. Some mesotheliomas stain for programmed death ligand-1 (PD-L1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To determine whether PD-L1 staining can separate mesotheliomas from reactive mesothelial proliferations (RMPs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>We stained 2 tissue microarrays containing in toto 62 malignant mesotheliomas and 88 RMPs, using anti-PD-L1 antibody 22C3. Staining was graded by using an immunoreactive score encompassing intensity\/distribution and was divided into negative, weak, moderate, and strong. Because PD-L1 staining can be heterogeneous, we also stained 10 whole sections of sarcomatoid\/desmoplastic mesotheliomas (SMMs) and 10 whole sections of spindled RMPs in the form of organizing pleuritis, the major morphologic differential of SMM. These 20 cases were not on the tissue microarrays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>RMPs showed generally negative, or occasionally weak staining in either the epithelioid or spindle cell compartments, whereas moderate to strong staining was seen in 10 of 14 SMMs but only in 6 of 48 epithelioid mesotheliomas (EMMs). The difference between SMM and RMP staining was statistically significant (P &amp;lt; .001), but between EMM and RMP was not significant. Whole section cases of organizing pleuritis showed no staining (N = 8) or weak staining (N = 2), whereas moderate\/strong staining was seen in 9 of 10 whole sections of SMMs, a statistically significant difference (P = .02). There were no \u201chot spots\u201d of RMP staining, suggesting that heterogeneous staining of RMPs is not a confounder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Strong diffuse PD-L1 staining using antibody 22C3 supports a diagnosis of SMM when the differential diagnosis is RMPs, but PD-L1 staining is not useful for separating EMMs from RMPs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2019-0370-oa","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T17:48:09Z","timestamp":1567619289000},"page":"185-188","source":"Crossref","is-referenced-by-count":15,"title":["Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions"],"prefix":"10.5858","volume":"144","author":[{"given":"Fatemeh","family":"Derakhshan","sequence":"first","affiliation":[{"name":"From the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Drs Derakhshan, Cheung, and Churg); and the Department of Pathology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada (Dr Ionescu)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Ionescu","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Drs Derakhshan, Cheung, and Churg); and the Department of Pathology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada (Dr Ionescu)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Cheung","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Drs Derakhshan, Cheung, and Churg); and the Department of Pathology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada (Dr Ionescu)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Churg","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Drs Derakhshan, Cheung, and Churg); and the Department of Pathology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada (Dr Ionescu)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","published-online":{"date-parts":[[2019,9,4]]},"reference":[{"issue":"4","key":"2020081300434416300_i1543-2165-144-2-185-b01","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New markers for separating benign from malignant mesothelial proliferations: are we there yet?","volume":"140","author":"Churg","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"6382","key":"2020081300434416300_i1543-2165-144-2-185-b02","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"6","key":"2020081300434416300_i1543-2165-144-2-185-b03","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","article-title":"Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC","volume":"16","author":"Camidge","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2020081300434416300_i1543-2165-144-2-185-b04","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2020081300434416300_i1543-2165-144-2-185-b05","doi-asserted-by":"crossref","first-page":"e1373235","DOI":"10.1080\/2162402X.2017.1373235","article-title":"The \u201cdon't eat me\u201d signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma","volume":"7","author":"Schurch","year":"2017","journal-title":"Oncoimmunology"},{"issue":"4","key":"2020081300434416300_i1543-2165-144-2-185-b06","doi-asserted-by":"crossref","first-page":"e0126029","DOI":"10.1371\/journal.pone.0126029","article-title":"Attenuated XPC expression is not associated with impaired DNA repair in bladder cancer","volume":"10","author":"Naipal","year":"2015","journal-title":"PLoS One"},{"key":"2020081300434416300_i1543-2165-144-2-185-b07","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13000-014-0221-9","article-title":"Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue\u2014a review","volume":"9","author":"Fedchenko","year":"2014","journal-title":"Diagn Pathol"},{"issue":"7","key":"2020081300434416300_i1543-2165-144-2-185-b08","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/PAS.0000000000001282","article-title":"Autoimmune pancreatitis type 2: utility of PD-L1 immunohistochemistry","volume":"43","author":"Gupta","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2020081300434416300_i1543-2165-144-2-185-b09","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"2020081300434416300_i1543-2165-144-2-185-b10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"},{"issue":"7","key":"2020081300434416300_i1543-2165-144-2-185-b11","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2020081300434416300_i1543-2165-144-2-185-b12","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jtho.2017.03.018","article-title":"PD-L1 testing for immune checkpoint inhibitors in mesothelioma: for want of anything better?","volume":"12","author":"Lantuejoul","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2020081300434416300_i1543-2165-144-2-185-b13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2020081300434416300_i1543-2165-144-2-185-b14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jtho.2018.01.020","article-title":"The PD-L1 immunohistochemistry biomarker: two steps forward, one step back?","volume":"13","author":"Kerr","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"5","key":"2020081300434416300_i1543-2165-144-2-185-b15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2019.02.001","article-title":"Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays","volume":"87","author":"Chapel","year":"2019","journal-title":"Hum Pathol"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/2\/185\/2500931\/arpa_2019-0370-oa.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/144\/2\/185\/2500931\/arpa_2019-0370-oa.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:36:47Z","timestamp":1764790607000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/144\/2\/article-p185.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,4]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,9,4]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2019-0370-oa","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,4]]}}}